AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04316195 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of the bulbocavernosus reflex
Description: According to the International Standards for Neurological Classification of Spinal Cord : The standard examination consists of the contraction of the bulbocavernous muscle following stimulation of the glans of the penis in men and of the clitoris in women.~By electromyography: The electromyography consists to stimulate the bulbocavernosus reflex with a bipolar probe apply on the glans for men, and on the clitoris in women. A surface electrode will be positioned on the right or left bulbocavernous muscle at the base of the penis (or vagina) and the anus for recording. The bulbocavernous reflex will be obtained by stimulation at a frequency of 1.5Hz and an amplitude of 14 to 47 mA.
Study NCT01858922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABVE-PC
Description: Doxorubicin (A) 25mg/m2/day IV over 10min on Day 1 \& Day 2~Bleomycin (B) 5units/m2/day IV over 10min on Day 1 10units/m2/day IV over 10min on Day 8~Vincristine (V) 1.4mg/m2/day IV push with extravasation precautions on Day 1 \& 8 (Max dose 2.8mg)~Etoposide (E) 125mg/m2/day IV over 1hr at a concentration of \</=0.4mg/ml in NS on Day 1, 2 \& 3~Prednisone (P) 40mg/m2/day PO divided in 2 doses every day on Day 1-7 IV equivalent of methylprednisolone is acceptable~Cyclophosphamide (C) 800 mg/m2 IV over 1 hr in 200 ml/m2 NS on Day 1
Study NCT01858922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DECA
Description: Dexamethasone (D):~10 mg/m2 IV over 15 minutes on Day 1 and Day 2, prior to Etoposide/Cytarabine.~Etoposide (E):~100 mg/m2 IV over 3 hours on Day 1 and Day 2 as continuous infusion mixed with cytarabine\*~Cytarabine (A):~3000 mg/m2 IV over 3 hours on Day 1 and Day 2 as continuous infusion mixed with etoposide\*~\*Mix together in NS at an etoposide concentration of \</=0.4 mg/ml~Dexamethasone eyedrops:~2 drops in each eye 4 times a day on Day 1, Day 2, and Day 3.~Cisplatin (C):~90 mg/m2 over 6 hours in 1000 ml/m2 NS + 10 gram/m2 mannitol on Day 1 as continuous infusion.
Study NCT01318161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine + opioid epidurally
Description: Epidural analgesia with local anesthetic + opioid
Study NCT01318161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine via PCA pump
Study NCT00096122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT02093273 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tOPV pilot batch
Description: the tOPV vaccine is given orally
Study NCT02093273 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: tOPV commercial batch
Description: tOPV vaccine is given orally
Study NCT03436732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMB-100
Description: administered on days 1, 3 and 5 of each 21 day cycle for up to 4 cycles
Study NCT03436732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL-110
Description: administered on day 1 of each cycle for up to 4 cycles
Study NCT01760863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Antibiotics
Description: Oral Antibiotics will be prescribed for 3 months per recommendations of an infectious disease specialist.
Study NCT03066180 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Viveve SUI treatment
Description: Non-ablative radiofrequency treatment with surface cooling
Study NCT01887223 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transconjunctival needling revision
Description: Surgical revision. A 25 Gauge needle was inserted under the subconjunctival space and perforate the encapsulated bled. The encapsulated bleb was ruptured with sweeping movement up and down, back and forth.
Study NCT04579588 — intervention group
Intervention type: BIOLOGICAL
Intervention: Flu shot
Description: All participants will receive a single shot of the flu vaccine
Study NCT01887223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical treatment
Description: Hypotensive eye drops are initialized one by one regarding intraocular pressure control. Nonspecific beta blocker and/or prostaglandin, followed by carbonic anhydrase inhibitors and/or selective alpha agonist.
Study NCT00434811 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Pancreatic Islet Cells
Description: 200 ml suspension of allogenic human purified islets
Study NCT00434811 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antithymocyte Globulin
Description: Participants will begin receiving ATG 2 days prior to the first islet transplant. ATG will continue to be given until Day 2 post-transplant.
Study NCT00434811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Participants will begin receiving sirolimus 2 days prior to the first islet transplant and will be given for the duration of the study.
Study NCT00434811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: On Day 1 post-transplant, participants will receive tacrolimus, which will also be taken for the duration of the study.
Study NCT00434811 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept will be taken on the day of transplant and Days 3, 7, and 10 post-transplant.
Study NCT00434811 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Islet Transplantation
Description: Transplantation of pancreatic islet cell
Study NCT00434811 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: Basiliximab will be used in place of ATG for the second and third transplants, if they are necessary.
Study NCT00605657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: Oral administration of valproic acid
Study NCT00605657 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT Scan
Description: CT scans were done before and after treating the patient with valproic acid
Study NCT00605657 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Sample
Description: Blood samples were collected before and after the intervention to monitor blood counts and biomarkers of ALPS
Study NCT02447406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6094
Study NCT02291874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipragliflozin
Description: oral
Study NCT01818661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-1451
Description: This is used to assess Tau burden in the brain.
Study NCT02447406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT02956564 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: intrauterine intervention
Description: choose different surgeries according to different causes
Study NCT00658073 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kidney transplantation with MSCs infusion
Description: Patients in Group A will receive the first MSCs infusion intravenously within 24 hours after kidney transplant operation , and the second infusion of MSCs will be performed two weeks later.
Study NCT00658073 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: kidney transplantation without MSC infusion
Description: kidney transplantation with standard immunosuppressive treatment regime
Study NCT00661180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexavar (Sorafenib, BAY43-9006)
Description: Patients will receive Bay 43-9006 400 mg po twice daily in a continuous, uninterrupted schedule. Treatment will continue until there is objective evidence of disease progression, or until evidence of toxicities that are unacceptable and thought to be related to study drug, which requires discontinuation of drug, or due to withdrawn patient consent.
Study NCT02758028 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brief counseling
Description: Peer counselling is delivered based on the queries and the needs of individual clients, according to the smoking status, dependency level and the perceived barriers of each individual with the use of motivational intervention approach.~The subjects will be followed up at 1-week, 1-, 3-, 6-, 9-, 12- and 24-month via telephone assessing their smoking status and reinforce intervention.
Study NCT01327729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated interferon alpha 2a YPEG-IFN α-2a 180mcg
Description: YPEG-IFN α-2a 180mcg dose form: subcutaneous dosage : 180 mcg frequency every week or ten days or 2 weeks according to the group
Study NCT01218321 — intervention group
Intervention type: BIOLOGICAL
Intervention: antiepileptic treatment
Description: White blood cells from peripheral blood samples
Study NCT04437745 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YVOIRE Y-Solution 720
Description: Hyaluronic acid dermal filler
Study NCT00692328 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa or acupuncture
Description: Comparison of subject expectancy of receiving levodopa or acupuncture.
Study NCT00692328 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Levodopa or acupuncture
Description: Comparison of subject expectancy of receiving levodopa or acupuncture.
Study NCT00692328 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Levodopa or acupuncture
Description: Comparison of subject expectancy of receiving levodopa or acupuncture.
Study NCT01273688 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eccentric training (Flex-Bar)
Description: 6x15 repetitions of supination and pronation daily over 12 weeks
Study NCT01273688 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric training (Flex-Bar)
Description: 6x15 repetitions of supination and pronation daily over 12 weeks
Study NCT01273688 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EpiHit elbow brace
Description: daily wearing of the EpiHit elbow brace
Study NCT01062451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril
Description: 8 mg taken orally from days 0 through 7.
Study NCT01062451 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment daily.
Study NCT01062451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan
Description: 16 mg taken orally from days 0 through 7.
Study NCT04434053 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIETHKE M.blue®
Description: The programmable shunt will be adjusted through the MIETHKE M.blue® valve.
Study NCT04434053 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MIETHKE proGAV 2.0® (with SA 2.0®)
Description: The programmable shunt will be adjusted through the MIETHKE proGAV 2.0® valve that will be implanted together with a shunt-assistant SA 2.0®.
Study NCT02674763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMGN779
Study NCT00433186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate 3000 mg each day
Study NCT01235637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alfentanil
Description: dosage form: injectable drug, opioid analgesic morphine, intravenous drug.~Dosage: 10μg/Kg, dilution: 1 ml = volume equivalent to 66μg or 10μg/kg = 1.43μg/kg fentanyl.~Frequency and duration: 2 bolus injection before 2 tracheal suctions at 0 and 4 hours respectively.
Study NCT01235637 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sufentanil
Description: dosage form: injectable drug, opioid analgesic morphine, intravenous drug.~Dosage: intravenous drug to 0,15 µg/Kg : Blisters of 10 ml, box of 20. MERCK~Frequency and duration: 2 bolus injection before 2 tracheal suctions at 0 and 4 hours respectively.
Study NCT02997007 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active tDCS
Description: Participants will receive active tDCS over the angular gyrus on five consecutive days
Study NCT02788760 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cervical collar (Miami J collar - Össur)
Description: The two groups of patients will similar in every way and will be treated with the same type of cervical collar - the only difference will be the length of treatment
Study NCT01470859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pramipexole
Description: tablets, 0.375mg-4.5mg/day divided by 3 times according to the optimal improvement of motor dysfunction in PD patients. duration is 1 year.
Study NCT01470859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sinemet CR
Description: tablet of Sinemet CR, dosage of levodopa ranging from 200mg-600mg/day divided by 2 or 3 times, Duration is 1 year
Study NCT03659955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous blood applied to dry eye
Description: See previous description for the study arm.
Study NCT03543189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Treatment with nivolumab will begin four weeks prior to the first brachytherapy treatment. Nivolumab will be given through a vein every 2 weeks for 4 courses. Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response, resulting in decreased tumor growth.
Study NCT02997007 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: Participants will receive sham tDCS over the angular gyrus on five consecutive days
Study NCT03543189 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: High dose rate (HDR) Brachytherapy involves the delivery of a high dose of radiation, internally, directly to the prostate. This procedure is completed in one day as an outpatient procedure.
Study NCT03543189 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: External beam radiation therapy to the participant's prostate will be given once a day, five days a week (Monday-Friday), for a total of five weeks. External radiation therapy treatments are given as an outpatient procedure and take about 10-15 minutes each day.
Study NCT03543189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy
Description: Standard of care.
Study NCT04117685 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: All groups will undergo observational data collection. No interventions will be made to patient care.
Study NCT01982578 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Genistein
Description: Subjects will be randomized 1:1 to receive 360 days of double blind treatment of genistein.
Study NCT01982578 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 360 days of double blind treatment of placebo.
Study NCT03979131 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Avelumab addition to perioperative chemotherapy in GC and GEJC
Description: Avelumab addition to perioperative chemotherapy in GC and GEJC. Peri-operatory treatment consisting of four cycles (each cycle is 14 days) of neoadjuvant chemotherapy (docetaxel, oxaliplatin and fluorouracil/leucovorin) plus avelumab previous to surgery. Surgery is recommended to be scheduled 4 to 6 weeks after the last dose. Afterwards (4 to 10 weeks after surgery), four cycles of adjuvant therapy with the same schema, followed by avelumab up to one year. There will be be a follow-up of 5 years.
Study NCT03049722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacemaker
Study NCT03227328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: concomitant cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor plus endocrine therapy
Description: CDK4/6 inhibitor:~* palbociclib~* ribociclib~* abemaciclib~Endocrine therapy:~* non-steroidal or steroidal AI~* fulvestrant
Study NCT03227328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy plus endocrine therapy (administered either concomitantly or sequentially)
Description: Standard Chemotherapy regimens will be classified as:~* anthracycline + taxane,~* taxane,~* anthracycline,~* capecitabine / fluoropyrimidines,~* others.~Endocrine therapy:~* non-steroidal or steroidal AI~* fulvestrant
Study NCT04210024 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diabetes Empowerment Education Program
Description: Individuals identified as Community Health Workers will participate in the Diabetes Empowerment Education Program (DEEP™). DEEP, is an education curriculum designed to help people with pre-diabetes, diabetes, relatives and caregivers gain a better understanding of diabetes self-care. Classes last a total of six weeks, providing participants with eight unique learning modules. Health literacy will be assessed before and after participating in DEEP.
Study NCT03643965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefecon
Description: Nefecon 16 mg for daily administration by mouth for 9 months.
Study NCT05059665 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Helio Liver Test
Description: De-identified whole blood and serum samples are collected for the purpose of evaluating the performance (sensitivity/specificity) of the HelioLiver Test for the detection of hepatocellular carcinoma (HCC).
Study NCT02940119 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multi Radiance Medical®
Description: Volunteers received all procedures of the study with active or placebo phototherapy (PBMT) in 9 sites of the neck and shoulders, twice a week. The PBMT was applied in all sessions.
Study NCT02940119 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Multi Radiance Medical®
Description: Volunteers received all procedures of the study with active or placebo phototherapy (PBMT) in 9 sites of the neck and shoulders, twice a week. The PBMT was applied in all sessions.
Study NCT03934619 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dolores One
Description: Dolores One, which is a will be applied personal sounds amplification device, will be used to determine if it improves the ability to communication and improves intelligibility
Study NCT01816399 — intervention group
Intervention type: PROCEDURE
Intervention: Routine coronary angiography
Study NCT03643965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo capsules for daily administration by mouth for 9 months.
Study NCT00459550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK933776
Description: Part A planned doses cohort 1 to cohort 3 0.001 mg/kg, 0.01 mg/kg and 0.1 mg/kg.~Part B planned doses cohort 4 to cohort 7 0.1 mg/kg, 1mg/kg, 3mg/kg and 10 mg/kg
Study NCT00459550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match GSK933776
Description: Part A first 2 cohorts 5 patients per cohort 2 placebo and 3 active third cohort part A 2 placebo 6 active. Part B 8 patients per cohort 2 placebo 6 active.
Study NCT02771327 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP plus Gas
Study NCT02771327 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ventimask plus gas
Study NCT04722393 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Exercise training
Study NCT01879826 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aculaser applied to kidney points
Description: The patient will receive aculaser, performed by licensed acupuncturist, to known kidney acupuncture sites. In addition, the patient will still receive standard pain control protocols with anesthetic medications like lidocaine plus ketamine or fentanyl and versed during the biopsy, along with pain management after the procedure.
Study NCT01879826 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Aculaser applied to sham points
Description: The patient will receive aculaser, performed by licensed acupuncturist, to sham acupuncture sites. In addition, the patient will still receive standard pain control protocols with anesthetic medications like lidocaine plus ketamine or fentanyl and versed during the biopsy, along with pain management after the procedure.
Study NCT01904279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive 162 mg of TCZ as SC injection Q3W or Q2W for 52 weeks
Study NCT00096122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Given IV
Study NCT04714255 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trace Image and Coloring for Kids-Book (TICK-B)
Description: A collection of images attractive that need to be colored, created as a book called TICK-B. This book was created with the instructions and recommendations of a pediatric psychiatrist and a professional drawing teacher at a children's school.Distraction with TICK-B began 1-3 min. before the intravenous cannula procedure and lasted until the end of the procedure.
Study NCT02598726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Given PO
Study NCT02598726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02598726 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Piperine Extract (Standardized)
Description: Given PO
Study NCT02598726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies